Efficacy of anti-obesity medication (AOM) and endoscopic gastric remodeling (EGR): Analysis of combination therapy with optimal timing and agents

Abstract

Background and study aims Endoscopic gastric remodeling (EGR) and anti-obesity medications (AOMs) are effective weight loss therapies. While the efficacy of EGR and AOMs has been established, the effect of combination therapy and its optimal approach remain unknown.

Patients and methods This was a single-center retrospective review of prospectively collected data from patients who underwent EGR. Patients were categorized as: 1) monotherapy – EGR alone; 2) combination therapy – an AOM prescribed within 6 months of EGR; and 3) sequential therapy – an AOM prescribed greater than 6 months of EGR. Outcomes included percent total weight loss (%TWL) at 12 months, response rate (≥ 10%TWL at 12 months), and serious adverse event rate.

Results A total of 208 patients were included. Of them, 65 (34%), 61 (31%), and 82 (35%) underwent monotherapy, combination therapy, and sequential therapy, respectively. At 12 months, patients who received EGR+GLP-1RA combination therapy achieved the greatest weight loss (23.7±4.6% TWL), while those who began with AOM followed by EGR more than 6 months later had the lowest weight loss (12.0±7.7%TWL) compared with monotherapy (17.3±10.0% TWL) (P = 0.04 and 0.03, respectively). The response rate was 100% for EGR+GLP-1RA combination therapy and 56% for AOM followed by EGR sequential therapy (P = 0.02).

Conclusions Combining AOM with EGR appears to result in greater weight loss compared with other strategies, with GLP-1RA as the preferred agent and optimal initiation of both therapies occurring within 6 months of each other. Prolonged medication use prior to EGR appears to be associated with suboptimal weight loss, suggesting the importance of early referral for adjunctive therapy.

Keywords

GI surgery - Endoscopy Upper GI Tract - Reflux disease - Quality and logistical aspects - Performance and complications

Publication History

Received: 05 July 2024

Accepted after revision: 07 November 2024

Accepted Manuscript online:
08 November 2024

Article published online:
17 December 2024

• References

• 1 World Health Organization. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
• 2 Ward ZJ, Bleich SN, Cradock AL. et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med 2019; 381: 2440-2450
• 3 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149: 367-378.e5
• 4 Jain P, Hejjaji V, Thomas MB. et al. Use of primary bariatric surgery among patients with obesity and diabetes. Insights from the Diabetes Collaborative Registry. Int J Obes 2005 2022; 46: 2163-2167
• 5 Jirapinyo P, Thompson CC. Endoscopic bariatric and metabolic therapies: surgical analogues and mechanisms of action. Clin Gastroenterol Hepatol 2017; 15: 619-630
• 6 Jirapinyo P, Hadefi A, Thompson CC. et al. American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity. Gastrointest Endosc 2024; 99: 867-885
• 7 Sharaiha RZ, Hajifathalian K, Kumar R. et al. Five-Year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol 2021; 19: 1051-1057.e2
• 8 Thompson C. Digestive Disease Week. Ten-year efficacy of endoscopic sleeve gastroplasty (ESG). https://eposters.ddw.org/ddw/2023/ddw-2023/378302
• 9 Jirapinyo P, Thompson CC. Obesity primer for the practicing gastroenterologist. Am J Gastroenterol 2021; 116: 918-934
• 10 Wilding JPH, Batterham RL, Calanna S. et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989-1002
• 11 Jastreboff AM, Aronne LJ, Ahmad NN. et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022; 387: 205-216
• 12 Wilding JPH, Batterham RL, Davies M. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022; 24: 1553-1564
• 13 Aronne LJ, Sattar N, Horn DB. et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA 2024; 331: 38-48
• 14 Kumar N, Abu Dayyeh BK, Lopez-Nava Breviere G. et al. Endoscopic sutured gastroplasty: procedure evolution from first-in-man cases through current technique. Surg Endosc 2018; 32: 2159-2164
• 15 Jirapinyo P, Thompson CC. Endoscopic gastric body plication for the treatment of obesity: technical success and safety of a novel technique (with video). Gastrointest Endosc 2020; 91: 1388-1394
• 16 Jirapinyo P, Thompson CC. Comparison of distal primary obesity surgery endolumenal techniques for the treatment of obesity (with videos). Gastrointest Endosc 2022; 96: 479-486
• 17 Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213
• 18 US Food and Drug Administration. What is a serious adverse event?. https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event
• 19 Apovian CM, Aronne LJ, Bessesen DH. et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 342-362
• 20 ElSayed NA, Aleppo G, Aroda VR. et al. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023. Diabetes Care 2023; 46: S140-S157
• 21 Badurdeen D, Hoff AC, Hedjoudje A. et al. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc 2021; 93: 1316-1324.e1
• 22 Buchwald H, Estok R, Fahrbach K. et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248-256.e5
• 23 Arterburn DE, Johnson E, Coleman KJ. et al. Weight outcomes of sleeve gastrectomy and gastric bypass compared to nonsurgical treatment. Ann Surg 2021; 274: e1269-e1276
• 24 Vargas EJ, Rizk M, Gomez-Villa J. et al. Effect of endoscopic sleeve gastroplasty on gastric emptying, motility and hormones: a comparative prospective study. Gut 2023; 72: 1073-1080
• 25 Abu Dayyeh BK, Acosta A, Camilleri M. et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol 2017; 15: 37-43.e1
• 26 Espinós JC, Turró R, Moragas G. et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes Surg 2016; 26: 1081-1089
• 27 Drucker DJ. Mechanisms of Action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27: 740-756
• 28 Jirapinyo P, Jaroenlapnopparat A, Zucker SD. et al. Combination therapy of endoscopic gastric remodeling with GLP-1RA for the treatment of MASLD. Obes Surg 2024; 34: 1471-1478